Pfizer, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Buy rating on the stock and has a $30.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evan Seigerman has given his Buy rating due to a combination of factors that underscore Pfizer’s strategic positioning and growth potential. The acquisition of Metsera by Pfizer was a competitive process, indicating strong interest in Metsera’s promising pipeline, particularly in the obesity market. This acquisition is expected to enhance Pfizer’s portfolio, providing significant opportunities for growth and expansion.
Furthermore, Seigerman’s analysis suggests that Pfizer’s shares are currently undervalued compared to its U.S. BioPharma peers. The potential for top-line growth and margin expansion appears to be underappreciated by the market. Additionally, Pfizer’s strategic acquisitions, fueled by the financial gains from COVID-related products, are expected to further strengthen its market position and drive future performance.
Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly & Co. According to TipRanks, Seigerman has an average return of 5.5% and a 50.12% success rate on recommended stocks.
In another report released on October 1, Jefferies also maintained a Buy rating on the stock with a $34.00 price target.